Filing Details

Accession Number:
0000950170-24-129709
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-11-21 16:04:21
Reporting Period:
2024-11-20
Accepted Time:
2024-11-21 16:04:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
818686 Teva Pharmaceutical Industries Ltd TEVA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1998173 Christine Fox C/O Teva Pharmaceutical Industries Ltd.
124 Dvora Hanevi'A St.,
Tel Aviv L3 6944020
Evp, Head Of U.s. Commercial No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2024-11-20 63,492 $0.00 63,492 No 4 M Direct
Ordinary Shares Disposition 2024-11-20 19,388 $16.87 44,104 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Restricted Share Units Disposition 2024-11-20 63,492 $0.00 63,492 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
190,476 No 4 M Direct
Footnotes
  1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 13, 2024.
  4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
  5. Restricted share units were granted on November 20, 2023, with 63,492 vested on November 20, 2024, and 63,492 vesting on each of November 20, 2025, November20, 2026 and November 20, 2027.